Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Cornell University | 9 |
| 2 | Kala Bio Inc | 2 |
| 3 | Princeton University | 2 |
Where innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 120 |
| 2 | A61P | Therapeutic activity (drug indications) | 86 |
| 3 | A23L | Foods and beverages (general) | 44 |
| 4 | A23V | Foods, foodstuffs - indexing scheme | 35 |
| 5 | A61Q | Cosmetics, personal care | 29 |
| 6 | A01N | Preservation of bodies; biocides; pest repellents | 21 |
| 7 | C07H | Sugars and derivatives | 13 |
| 8 | C12N | Microorganisms, enzymes | 10 |
| 9 | C07K | Peptides | 6 |
| 10 | C07F | Organometallic compounds | 5 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Blood vessel relaxational agent containing decursin or decursinol angelate for the prevention or treatment of blood vessel disease | 2004 | 6 | |
| Application of decursinol angelate in preparation of anti-atherosclerosis medicine | 2018 | 4 | |
| COMPOSITIONS FOR URINARY DYSFUNCTION AND EDEMA CONTAINING DECURSIN AND/OR DECURSINOL ANGELATE, OR ANGELICA EXTRACT CONTAINING DECURSIN AND /OR DECURSINOL ANGELATE | 2005 | 3 | |
| BLOOD VESSEL RELAXATIONAL AGENT CONTAINING DECURSIN OR DECURSINOL ANGELATE | 2005 | 3 | |
| COMPOSITION OF TREATMENT FOR VEGF-INDUCED ANGIOGENESIS-RELATED DISEASES CONTAINING DECURSIN AND DECURSINOL ANGELATE | 2010 | 1 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 8 |
| 2017 | 7 |
| 2018 | 9 |
| 2019 | 6 |
| 2020 | 10 |
| 2021 | 7 |
| 2022 | 5 |
| 2023 | 4 |
| 2024 | 8 |
| 2025 | 5 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Junxuan Lü | University of Minnesota | 14 |
| 2 | Gyu‐Yong Song | Chungnam National University | 14 |
| 3 | Cheng Jiang | University of Minnesota | 11 |
| 4 | Chengguo Xing | University of Minnesota | 8 |
| 5 | Sung‐Hoon Kim | Kyung Hee University | 8 |
| 6 | Jung‐woo Chae | Chungnam National University | 6 |
| 7 | You Mie Lee | Kyungpook National University | 6 |
| 8 | Sun Chul Kang | Daegu University | 4 |
| 9 | In‐Soo Yoon | Pusan National University | 4 |
| 10 | In‐hwan Baek | Yuhan University | 4 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| A Novel Anticancer Agent, Decursin, Induces G1 Arrest and Apoptosis in Human Prostate Carcinoma Cells | 2005 | 197 | Cancer-related Molecular Pathways |
| Anti-tumor activities of decursinol angelate and decursin fromAngelica gigas | 2003 | 134 | Plant chemical constituents analysis |
| Decursin: A Cytotoxic Agent and Protein Kinase C Activator from the Root ofAngelica gigas | 1996 | 130 | Plant Pathogens and Fungal Diseases |
| Potent Antiandrogen and Androgen Receptor Activities of an Angelica gigas –Containing Herbal Formulation: Identification of Decursin as a Novel and Active Compound with Implications for Prevention and Treatment of Prostate Cancer | 2006 | 122 | Prostate Cancer Treatment and Research |
| Decursin Inhibits Induction of Inflammatory Mediators by Blocking Nuclear Factor-κB Activation in Macrophages | 2006 | 112 | Inflammatory mediators and NSAID effects |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of Decursinol Angelate?
Which universities hold the most patents related to Decursinol Angelate?
Which researchers have published the most papers on Decursinol Angelate?
What are the main patent classification areas for Decursinol Angelate research?
What research trends are evident in Decursinol Angelate publications and patents?